Mainz Biomed to Appear on ClearThink IR’s Virtual Live Event on Wednesday, March 1, 2023 at 12 Noon ET
February 28 2023 - 8:01AM
Mainz Biomed N.V., a molecular genetics diagnostic company
specializing in the early detection of cancer, today announced that
its Chief Financial Officer Bill Caragol will appear on ClearThink
IR Virtual Live on Wednesday, March 1, 2023 at 12 noon ET.
The ClearThink IR Virtual Live, powered by
Paltalk, is hosting a different CEO every Wednesday at 12 noon ET
for a “fireside chat” followed by an engaging Q&A chat
discussion offering a great opportunity for potential investors to
learn about a company’s product or service offerings and strategic
initiatives of an emerging growth micro-cap company.
Please click on this link to sign up and install
Paltalk to register for the ClearThink Capital IR room:
https://invite.paltalk.net/ClearThinkCapital.
Step 1 – Click the link to download and install
the Paltalk appStep 2 – After creating an account on Paltalk,
you’ll be brought to “ClearThink Capital”Step 3 – Follow the room
and join us on: Wednesday, March 1, 2023 at 12pm noon ET
About ColoAlertColoAlert detects colorectal
cancer (CRC) via a simple-to-administer test with a sensitivity and
specificity nearly as high as the invasive colonoscopy (Dollinger
MM et al., 2018). The test utilizes proprietary methods to analyze
cell DNA for specific tumor markers combined with the fecal
immunochemical test (FIT). It is designed to detect tumor DNA and
CRC cases in their earliest stages. The product is CE-IVDR marked
(complying with EU safety, health and environmental requirements)
and commercially available in a selection of countries in the
European Union and the United Arab Emirates. Mainz Biomed currently
distributes ColoAlert through a number of clinical affiliates. If
approved in the United States, the Company’s commercial strategy is
to establish scalable distribution through a collaborative partner
program with regional and national laboratory service providers
across the country.
About Colorectal CancerAccording to the Centers
for Disease Control and Prevention (“CDC”), CRC is the second most
lethal cancer in the United States and Europe, but also the most
preventable, with early detection providing survival rates above
90%. The American Cancer Society estimated that in 2021 there were
approximately 149,500 new cases of colon and rectal cancer in the
US, with 52,980 resulting in death. Recent decisions by the
U.S. Food and Drug Administration (FDA) suggest that screening with
stool DNA tests such as ColoAlert in the United States should be
conducted once every three years starting at age 45. Currently,
there are 112 million Americans aged 50+, a total that is expected
to increase to 157 million within 10 years and a US market
opportunity of approximately $3.7 billion per year.
About Mainz Biomed N.V.Mainz Biomed develops
market-ready molecular genetic diagnostic solutions for
life-threatening conditions. The Company’s flagship product is
ColoAlert, an accurate, non-invasive and easy-to-use,
early-detection diagnostic test for CRC. ColoAlert is currently
marketed across Europe and in select international territories. The
Company is currently running a pivotal FDA clinical study for U.S.
regulatory approval. Mainz Biomed’s product candidate portfolio
also includes PancAlert, an early-stage pancreatic cancer screening
test based on real-time PCR multiplex detection of
molecular-genetic biomarkers in stool samples. To learn more, visit
mainzbiomed.com or follow us on
LinkedIn,
Twitter and
Facebook.
For media inquiries, please
contact press@mainzbiomed.com In Europe:MC Services
AGAnne Hennecke/Caroline Bergmann+49 211 529252
20mainzbiomed@mc-services.euIn the US:Spectrum ScienceMelissa
Laverty/Valerie Enes+1 540 272 6465mainz@spectrumscience.com
For investor inquiries, please
contact info@mainzbiomed.comForward-Looking
StatementsCertain statements made in this press release
are “forward-looking statements” within the meaning of the “safe
harbor” provisions of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements may be identified by the use of
words such as “anticipate”, “believe”, “expect”, “estimate”,
“plan”, “outlook”, and “project” and other similar expressions that
predict or indicate future events or trends or that are not
statements of historical matters. These forward-looking statements
reflect the current analysis of existing information and are
subject to various risks and uncertainties. As a result, caution
must be exercised in relying on forward-looking statements. Due to
known and unknown risks, actual results may differ materially from
the Company’s expectations or projections. The following factors,
among others, could cause actual results to differ materially from
those described in these forward-looking statements: (i) the
failure to meet projected development and related targets; (ii)
changes in applicable laws or regulations; (iii) the effect of the
COVID-19 pandemic on the Company and its current or intended
markets; and (iv) other risks and uncertainties described herein,
as well as those risks and uncertainties discussed from time to
time in other reports and other public filings with the Securities
and Exchange Commission (the “SEC”) by the Company. Additional
information concerning these and other factors that may impact the
Company’s expectations and projections can be found in its initial
filings with the SEC, including its annual report on Form 20-F
filed on May 5, 2022. The Company’s SEC filings are available
publicly on the SEC’s website at www.sec.gov. Any
forward-looking statement made by us in this press release is based
only on information currently available to Mainz Biomed and speaks
only as of the date on which it is made. Mainz Biomed undertakes no
obligation to publicly. update any forward-looking statement,
whether written or oral, that may be made from time to
time, whether as a result of new information, future developments
or otherwise, except as required by law.
Mainz BioMed NV (NASDAQ:MYNZ)
Historical Stock Chart
From Aug 2024 to Sep 2024
Mainz BioMed NV (NASDAQ:MYNZ)
Historical Stock Chart
From Sep 2023 to Sep 2024